Menü
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von HC Wainwright 

Crinetics Pharmaceuticals Inc diskutieren

Crinetics Pharmaceuticals Inc

WKN: A2JQTJ / Symbol: CRNX / Name: Crinetics Pharmaceuticals / Aktie / Small Cap /

43,00 €
-0,95 %

Einschätzung Buy
Rendite (%) 66,67 %
Kursziel 69,23
Veränderung
Endet am 27.06.26

Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $81.00 price target on the stock.
Ratings data for CRNX provided by MarketBeat

Einschätzung Buy
Rendite (%) 41,45 %
Kursziel 44,06
Veränderung
Endet am 24.09.26

Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target lowered by analysts at JPMorgan Chase & Co. from $53.00 to $52.00. They now have an "overweight" rating on the stock.
Ratings data for CRNX provided by MarketBeat

Einschätzung Buy
Rendite (%) 6,67 %
Kursziel 53,13
Veränderung
Endet am 26.09.26

Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Robert W. Baird from $58.00 to $62.00. They now have an "outperform" rating on the stock.
Ratings data for CRNX provided by MarketBeat

Einschätzung Buy
Rendite (%) 11,98 %
Kursziel 75,07
Veränderung
Endet am 29.09.26

Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Leerink Partners from $80.00 to $88.00. They now have an "outperform" rating on the stock.
Ratings data for CRNX provided by MarketBeat

Einschätzung Buy
Rendite (%) 14,97 %
Kursziel 65,69
Veränderung
Endet am 29.09.26

Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Morgan Stanley from $65.00 to $77.00. They now have an "overweight" rating on the stock.
Ratings data for CRNX provided by MarketBeat

Einschätzung Buy
Rendite (%) 21,47 %
Kursziel 74,23
Veränderung
Endet am 30.09.26

Crinetics Pharmaceuticals (NASDAQ:CRNX) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $73.00 to $87.00. They now have an "outperform" rating on the stock.
Ratings data for CRNX provided by MarketBeat